Skip to main content
Equibles
NKTR logo

NKTR · Nektar Therapeutics · Metrics

Track NKTR — free

Use NKTR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NKTR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$39.22 +2.58 (+7.04%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$1.25B
Shares
34.14M
Volume · Oct 20 1.06M Avg daily vol (3M) 1.12M

NKTR metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$39.22
Market cap
$1.25B

Price action

20 metrics
Price change (1W)
-8.0%
Price change (30D)
-45.2%
Price change (3M)
-43.5%
Price change (6M)
-63.5%
Price change (YTD)
-13.3%
Price change (1Y)
-36.6%
Trailing year
Price change (5Y)
—
52-week high
$100.35
52-week low
$35.12
Change from 52-week high
-63.5%
Change from 52-week low
+4.3%
Annualized volatility
85.2%
Annualized volatility (3M)
63.6%
Beta
1.0
RSI (14D)
23.2
Price vs SMA 50
-41.1%
Price vs SMA 200
-43.7%
Avg volume (3M)
1.11M
Relative volume
0.8
Average dollar volume
$65.58M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
34.14M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
22.9×
reciprocal yield 4.4%
P / book
1.4
reciprocal yield 72.2%
FCF yield
-18.7%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
100.0%
Operating margin
-257.8%
Trailing 12 months
Net margin
-287.8%
Gross profit (TTM)
$2.97M
Operating profit (TTM)
−$140.73M
Net income (TTM)
−$157.13M
Trailing 12 months
Diluted EPS (TTM)
$-6.21
FCF margin
-428.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.44
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-5.89
EBITDA per diluted share (TTM)
$-5.86
Net income per diluted share (TTM)
$-6.70
Operating cash flow per diluted share (TTM)
$-9.86
Free cash flow per diluted share (TTM)
$-9.87
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$5.53
Stock compensation per diluted share (TTM)
—
Book value per share
$4.41

Growth

11 metrics
Revenue growth YoY
-9.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$54.59M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+134.6%
Year over year · more shares
Revenue CAGR (3Y)
-15.7%
Revenue CAGR (5Y)
-18.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-17.4%
Return on assets
-14.3%
Debt / equity
—
Current ratio
10.4
EBITDA (TTM)
−$140.04M
Free cash flow (TTM)
−$234.03M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$39.27M
Total assets
$1.10B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$233.79M
Capital expenditures (TTM)
$244,000
R&D (TTM)
$131.77M
SG&A (TTM)
—
Stock compensation (TTM)
$18.23M
R&D / revenue
241.4%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
243
13F filer change QoQ
+25
Institutional ownership
111.5%
Conviction holders (share of 13F filers)
4.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+17.1%
Holder tenure
11.1
Price vs estimated holder cost
+22.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.7%

Short interest

3 metrics
Short interest
20.4%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$43,476
Insider-sentiment score
49 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 906709 CUSIP 640268306 13F (30d) 14 filings 14 filers Visit website Investor relations